Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of E2007 up to 12 mg in refractory partial seizures
2006-003702-26Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2006
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in epilepsy comparing E2007 up to 12 mg/day with Placebo (2 arms). Primary endpoint: Seizure counts. Started Oct 2006; status: completed.
02
Drugs
perampanel
03
Conditions
epilepsy
Beyond the preview
Go deeper on 2006-003702-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003702-26.